Involvement of Ceramide Signalling in Radiation-Induced Tumour Vascular Effects and Vascular-Targeted Therapy

Int J Mol Sci. 2022 Jun 15;23(12):6671. doi: 10.3390/ijms23126671.

Abstract

Sphingolipids are well-recognized critical components in several biological processes. Ceramides constitute a class of sphingolipid metabolites that are involved in important signal transduction pathways that play key roles in determining the fate of cells to survive or die. Ceramide accumulated in cells causes apoptosis; however, ceramide metabolized to sphingosine promotes cell survival and angiogenesis. Studies suggest that vascular-targeted therapies increase endothelial cell ceramide resulting in apoptosis that leads to tumour cure. Specifically, ultrasound-stimulated microbubbles (USMB) used as vascular disrupting agents can perturb endothelial cells, eliciting acid sphingomyelinase (ASMase) activation accompanied by ceramide release. This phenomenon results in endothelial cell death and vascular collapse and is synergistic with other antitumour treatments such as radiation. In contrast, blocking the generation of ceramide using multiple approaches, including the conversion of ceramide to sphingosine-1-phosphate (S1P), abrogates this process. The ceramide-based cell survival "rheostat" between these opposing signalling metabolites is essential in the mechanotransductive vascular targeting following USMB treatment. In this review, we aim to summarize the past and latest findings on ceramide-based vascular-targeted strategies, including novel mechanotransductive methodologies.

Keywords: apoptosis; cell death; ceramide; endothelial cell; ultrasound-stimulated microbubbles; vascular damage.

Publication types

  • Review

MeSH terms

  • Ceramides / metabolism
  • Endothelial Cells* / metabolism
  • Humans
  • Lysophospholipids / metabolism
  • Neoplasms, Radiation-Induced*
  • Signal Transduction
  • Sphingolipids / metabolism
  • Sphingosine / metabolism

Substances

  • Ceramides
  • Lysophospholipids
  • Sphingolipids
  • Sphingosine

Grants and funding

This work was supported by the Terry Fox Foundation. Dr. Gregory Czarnota is a recipient of a James and Mary Davie Chair in Breast Cancer Imaging and Ablation from the University of Toronto.